Skip to main content
Log in

Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Myeloid-derived suppressor cells (MDSCs) accumulate in cancer patients and tumor-bearing mice, subsequently suppressing the host immune system. MDSCs represent a group of immature myeloid cells expressing CD11b and Gr-1. Here, we show that a Toll-like receptor (TLR) agonist, resiquimod, which binds to TLR7 and TLR8, induces the differentiation of MDSCs into mature myeloid cells. MDSCs were isolated from mice bearing mammary carcinoma 4T1 cells, and the purified MDSCs were cultured in the presence of resiquimod for 5 days. Phenotypic analysis showed that the resiquimod-treated MDSCs differentiated into F4/80+ macrophages and CD11c+/I-Ad+ dendritic cells. Functional analysis showed that the MDSCs also lost their suppressive activity on T cells. Resiquimod-treated MDSCs significantly enhanced the proliferation of T cells that were treated with anti-CD3 and anti-CD28 monoclonal antibodies. These results show that resiquimod induces the differentiation of MDSCs into macrophages and dendritic cells, and also suggest that resiquimod may improve cancer immunotherapy by reducing immunosuppressive MDSCs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Almand, B., J.I. Clark, E. Nikitina, J. van Beynen, N.R. English, S.C. Knight, D.P. Carbone, and D.I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of Immunology 166: 678–689.

    Article  CAS  Google Scholar 

  • Assier, E., V. Marin-Esteban, A. Haziot, E. Maggi, D. Charron, and N. Mooney. 2007. TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation. Journal of Leukocyte Biology 81: 221–228.

    Article  CAS  PubMed  Google Scholar 

  • Bunt, S.K., P. Sinha, V.K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology 176: 284–290.

    Article  CAS  Google Scholar 

  • Burns Jr, R.P., B. Ferbel, M. Tomai, R. Miller, and A.A. Gaspari. 2000. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans’ cells. Clinical Immunology 94: 13–23.

    Article  CAS  PubMed  Google Scholar 

  • Chuang, T.H., and R.J. Ulevitch. 2000. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. European Cytokine Network 11: 372–378.

    CAS  PubMed  Google Scholar 

  • Dockrell, D.H., and G.R. Kinghorn. 2001. Imiquimod and resiquimod as novel immunomodulators. Journal of Antimicrobial Chemotherapy 48: 751–755.

    Article  CAS  PubMed  Google Scholar 

  • Gabrilovich, D.I., V. Bronte, S.H. Chen, M.P. Colombo, A. Ochoa, S. Ostrand-Rosenberg, and H. Schreiber. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Research 67: 425.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gabrilovich, D.I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 9: 162–174.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gabrilovich, D.I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology 12: 253–268.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gorden, K.B., K.S. Gorski, S.J. Gibson, R.M. Kedl, W.C. Kieper, X. Qiu, M.A. Tomai, S.S. Alkan, and J.P. Vasilakos. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. The Journal of Clinical Immunology 174: 1259–1268.

    CAS  Google Scholar 

  • Hackstein, H., A. Knoche, A. Nockher, J. Poeling, T. Kubin, M. Jurk, J. Vollmer, and G. Bein. 2011. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation. Cellular Immunology 271: 401–412.

    Article  CAS  PubMed  Google Scholar 

  • Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nature Immunology 5: 987–995.

    Article  CAS  PubMed  Google Scholar 

  • Jurk, M., F. Heil, J. Vollmer, C. Schetter, A.M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nature Immunology 3: 499.

    Article  CAS  PubMed  Google Scholar 

  • Kanzler, H., F.J. Barrat, E.M. Hessel, and R.L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Medicine 13: 552–559.

    Article  CAS  PubMed  Google Scholar 

  • Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research 63: 4441–4449.

    CAS  PubMed  Google Scholar 

  • Le, H.K., L. Graham, E. Cha, J.K. Morales, M.H. Manjili, and H.D. Bear. 2009. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. International Immunopharmacology 9: 900–909.

    Article  CAS  PubMed  Google Scholar 

  • Lee, J.K., M.K. Lee, Y.P. Yun, Y. Kim, J.S. Kim, Y.S. Kim, K. Kim, S.S. Han, and C.K. Lee. 2001. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. International Immunopharmacology 1: 1275–1284.

    Article  CAS  PubMed  Google Scholar 

  • Lee, Y.R., Y.H. Lee, K.H. Kim, S.A. Im, and C.K. Lee. 2013. Induction of potent antigen-specific cytotoxic T cell response by PLGA-nanoparticles containing antigen and TLR agonist. Immune Network 13: 30–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nagaraj, S., J.I. Youn, H. Weber, C. Iclozan, L. Lu, M.J. Cotter, C. Meyer, C.R. Becerra, M. Fishman, S. Antonia, M.B. Sporn, K.T. Liby, B. Rawal, J.H. Lee, and D.I. Gabrilovich. 2010. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical Cancer Research 16: 1812–1823.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ostrand-Rosenberg, S., P. Sinha, O. Chornoguz, and C. Ecker. 2012. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunology, Immunotherapy 61: 1319–1325.

    Article  CAS  PubMed  Google Scholar 

  • Park, M.H., Y.J. Jung, and P.H. Kim. 2012. Newly identified TLR9 stimulant, M6-395, is a potent polyclonal activator for murine B cells. Immune Network 12: 27–32.

    Article  PubMed Central  PubMed  Google Scholar 

  • Rabinovich, G.A., D. Gabrilovich, and E.M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology 25: 267–296.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Serafini, P., I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology 16: 53–65.

    Article  CAS  PubMed  Google Scholar 

  • Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. The Journal of Clinical Investigation 117: 1155–1166.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sinha, P., V.K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. Journal of Immunology 174: 636–645.

    Article  CAS  Google Scholar 

  • Stanley, M.A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clinical and Experimental Dermatology 27: 571–577.

    Article  CAS  PubMed  Google Scholar 

  • Suzuki, E., V. Kapoor, A.S. Jassar, L.R. Kaiser, and S.M. Albelda. 2005. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research 11: 6713–6721.

    Article  CAS  PubMed  Google Scholar 

  • Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annual Review of Immunology 21: 335–376.

    Article  CAS  PubMed  Google Scholar 

  • Thomsen, L.L., P. Topley, M.G. Daly, S.J. Brett, and J.P. Tite. 2004. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22: 1799–1809.

    Article  CAS  PubMed  Google Scholar 

  • Vasilakos, J.P., and M.A. Tomai. 2013. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Review of Vaccines 12: 809–819.

    Article  CAS  PubMed  Google Scholar 

  • Wiers, K.M., D.M. Lathers, M.A. Wright, and M.R. Young. 2000. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. Journal of Immunotherapy 23: 115–124.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant from the Next-Generation BioGreen 21 Program (PJ009619), Rural Development Administration, Republic of Korea and by the Ministry of Knowledge Economy (MKE), Korea Institute for Advancement of Technology (KIAT) through the Inter-ER Cooperation Projects (R0002019).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chong-Kil Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, M., Park, CS., Lee, YR. et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch. Pharm. Res. 37, 1234–1240 (2014). https://doi.org/10.1007/s12272-014-0379-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-014-0379-4

Keywords

Navigation